Immunovant (IMVT) closed at $29.17 on October 30, 2026, down 1.6% from the previous close, on volume of 1,125,532 shares (30-day average 1,500,671).
Data as of October 30, 2026.
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
PRNewswire (Mon, 12-Oct 7:35 PM ET)
Business Wire (Sun, 11-Oct 5:43 PM ET)
PRNewswire (Fri, 25-Sep 1:55 PM ET)
Globe Newswire (Wed, 23-Sep 7:00 AM ET)
Globe Newswire (Thu, 6-Aug 7:00 AM ET)
Market Chameleon (Wed, 20-May 3:31 AM ET)
Market Chameleon (Thu, 2-Apr 3:05 AM ET)
Immunovant’s $550 Million Stock Offering Extends Cash Runway Toward Graves’ Disease Launch
Market Chameleon (Thu, 11-Dec 6:12 AM ET)
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Immunovant trades on the NASDAQ stock market under the symbol IMVT.
As of October 30, 2026, IMVT stock price declined to $29.17 with 1,125,532 million shares trading.
IMVT has a beta of 1.75, meaning it tends to be more sensitive to market movements. IMVT has a correlation of 0.13 to the broad based SPY ETF.
IMVT has a market cap of $6.03 billion. This is considered a Mid Cap stock.
In the last 3 years, IMVT traded as high as $45.58 and as low as $12.72.
The top ETF exchange traded funds that IMVT belongs to (by Net Assets): VTI, VB, XBI, IWM, VBK.
IMVT has outperformed the market in the last year with a price return of +34.7% while the SPY ETF gained +11.0%. However, in the short term, IMVT had mixed performance relative to the market. It has underperformed in the last 3 months, returning -24.4% vs +3.9% return in SPY. But in the last 2 weeks, IMVT shares have fared better than the market returning +6.0% compared to SPY -2.1%.
IMVT support price is $28.86 and resistance is $30.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMVT shares will trade within this expected range on the day.
